$AMGN

Miller Derek sold $1.6M of AMGN

Miller Derek (SVP, Human Resources) sold 3,890 shares of AMGEN INC (AMGN) at $402.54 ($1.57M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Miller Derek
Published Aug 7, 2026, 10:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMGN
Neutral
medium confidence
Mentioned
$AMGN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

It provides transaction-level details (shares, price, total value, post-sale holdings) but no accompanying company event such as guidance, trial results, or regulatory action.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no fundamental catalyst in the disclosure.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total holdings or compensation, signal strength is limited.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after 2026-08-06 insider sale

Background

The article is a SEC Form 4 insider transaction disclosure for Amgen (AMGN).

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

AMGN disclosed an insider open-market sale by SVP Human Resources Miller Derek of 3,890 shares at about $402.54 on 2026-08-06.

Expected impact

Likely minimal near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 insider sales are common and the filing provides transaction details without earnings, guidance, or operational changes. The absence of a 10b5-1 plan can raise attention, but the article contains no additional catalyst or company-specific news.

Market effects

No clear sector read-through from a single AMGN insider sale.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could be interpreted by some traders as higher near-term risk, even if the sale size is not clearly material to AMGN’s fundamentals.

Key entities

  • AMGN

    Amgen Inc., the company whose insider transaction was reported.

  • Miller Derek

    SVP, Human Resources at Amgen, reported an open-market sale of shares.

Related articles

$AMGNMed

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen (AMGN) shares rose about 6.7% after the EMA CHMP issued a positive opinion to expand Repatha’s use in Europe for adults with or at high risk for atherosclerotic cardiovascular disease, based on Phase 3 VESALIUS-CV results. If approved by the European Commission, it could widen the eligible patient pool. The article cites Q2 2026 revenue of $10,054 million and net income of $2,375 million.

$AMGNHighAI 9/10

Why Amgen (AMGN) Stock Is Trading Up Today

Amgen (AMGN) shares rose about 3.5% after the company reported Q2 2026 results that beat expectations and raised full-year guidance. Revenue grew 9.5% to $10.05B, adjusted EPS was $6.29, and free cash flow margin improved to 34.7%. Amgen lifted FY revenue guidance to $38.8B and adjusted EPS to $22.90 midpoint.

$GOOGLMed

Stocks making the biggest moves midday: Alphabet, SpaceX, Shopify, Newmont, Insulet, AMD & more

Midday movers included Alphabet, down over 4%, after it reshuffled its AI units and said chief scientist Jeff Dean will leave. Gold miners rose as gold futures hit a June high; VanEck Gold Miners ETF (GDX) gained 6.8%. SpaceX shares fell 8% after its IPO-era first quarterly report showed $7.81B revenue and $18.37B capex. Shopify surged ~17% on guidance; Insulet fell over 20% after lowering 2026 Omnipod growth.

$AMGNHighAI 9/10

Why is Amgen stock surging today?

Amgen (AMGN) shares rose 6.2% to a 52-week high of $416.22 after the company reported Q2 2026 results that beat Wall Street and raised guidance. Adjusted EPS was $6.29 and revenue rose 10% to $10.05B. Full-year revenue guidance increased to $38.2B-$39.4B and adjusted EPS to $22.30-$23.50. Analysts lifted price targets.